Single molecule molecular inversion probes for high throughput germline screenings in dystonia

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pogoda, Michaela
• dc.contributor.author Hilke, Franz-Joachim
• dc.contributor.author Lohmann, Ebba
• dc.contributor.author Sturm, Marc
• dc.contributor.author Lenz, Florian
• dc.contributor.author Matthes, Jakob
• dc.contributor.author Muyas Remolar, Francesc, 1992-
• dc.contributor.author Ossowski, Stephan
• dc.contributor.author Hoischen, Alexander
• dc.contributor.author Faust, Ulrike
• dc.contributor.author Sepahi, Ilnaz
• dc.contributor.author Casadei, Nicolas
• dc.contributor.author Poths, Sven
• dc.contributor.author Riess, Olaf
• dc.contributor.author Schroeder, Christopher
• dc.contributor.author Grundmann, Kathrin
• dc.date.accessioned 2020-03-24T08:18:37Z
• dc.date.available 2020-03-24T08:18:37Z
• dc.date.issued 2019
• dc.description.abstract Background: This study's aim was to investigate a large cohort of dystonia patients for pathogenic and rare variants in the ATM gene, making use of a new, cost-efficient enrichment technology for NGS-based screening. Methods: Single molecule Molecular Inversion Probes (smMIPs) were used for targeted enrichment and sequencing of all protein coding exons and exon-intron boundaries of the ATM gene in 373 dystonia patients and six positive controls with known ATM variants. Additionally, a rare-variant association study was performed. Results: One patient (0.3%) was compound heterozygous and 21 others were carriers of variants of unknown significance (VUS) in the ATM gene. Although mutations in sporadic dystonia patients are not common, exclusion of pathogenic variants is crucial to recognize a potential tumor predisposition syndrome. SmMIPs produced similar results as routinely used NGS-based approaches. Conclusion: Our results underline the importance of implementing ATM in the routine genetic testing of dystonia patients and confirm the reliability of smMIPs and their usability for germline screenings in rare neurodegenerative conditions.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pogoda M, Hilke FJ, Lohmann E, Sturm M, Lenz F, Matthes J, Muyas F, Ossowski S, Hoischen A, Faust U, Sepahi I, Casadei N, Poths S, Riess O, Schroeder C, Grundmann K. Single molecule molecular inversion probes for high throughput germline screenings in dystonia. Front Neurol. 2019; 10:1332. DOI: 10.3389/fneur.2019.01332
• dc.identifier.doi http://dx.doi.org/10.3389/fneur.2019.01332
• dc.identifier.issn 1664-2295
• dc.identifier.uri http://hdl.handle.net/10230/44008
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Front Neurol. 2019; 10:1332
• dc.rights © 2019 Pogoda, Hilke, Lohmann, Sturm, Lenz, Matthes, Muyas, Ossowski, Hoischen, Faust, Sepahi, Casadei, Poths, Riess, Schroeder and Grundmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword ATM
• dc.subject.keyword MIPs
• dc.subject.keyword NGS
• dc.subject.keyword Ataxia-telangiectasia
• dc.subject.keyword Dystonia
• dc.title Single molecule molecular inversion probes for high throughput germline screenings in dystonia
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion